A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 30 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Mar 2017 This trial has been completed in Belgium (end date: 21 Dec 2016) and Germany (end date: 21 Dec 2016).
- 30 Nov 2016 According to European Clinical Trials Database record, trial has been completed in Poland.